FDA Approps Amendment Targets Chief Counsel Troy
This article was originally published in The Gray Sheet
Executive Summary
FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts